文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

恢复期血浆治疗与COVID-19患者临床结局的关联:系统评价与Meta分析

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA · 2021-01-01
一句话结论恢复期血浆与安慰剂或标准治疗相比,未显著降低COVID-19患者全因死亡率,其他临床结局亦无显著获益。

该系统评价与Meta分析检索至2021年1月29日,纳入比较恢复期血浆与安慰剂或标准治疗的随机对照试验。主要分析仅纳入4项同行评议RCT(1060例),全因死亡RR 0.93(95%CI 0.63-1.38),绝对风险差-1.21%(95%CI -5.29%-2.88%),证据确定性低(不精确)。纳入全部10项RCT(10722例)的次要分析RR 1.02(95%CI 0.92-1.12),证据确定性中等(因纳入未发表数据)。其他结局如机械通气RR 0.76(95%CI 0.20-2.87)等均无显著差异。

要点

  • 4项同行评议RCT(1060例)中,恢复期血浆组全因死亡RR 0.93(95%CI 0.63-1.38),绝对风险差-1.21%(95%CI -5.29%-2.88%),证据确定性低。
  • 全部10项RCT(10722例)中,全因死亡RR 1.02(95%CI 0.92-1.12),证据确定性中等。
  • 机械通气使用RR 0.76(95%CI 0.20-2.87),绝对风险差-2.56%(95%CI -13.16%-8.05%),证据确定性低。
  • 住院时长HR 1.17(95%CI 0.07-20.34),证据确定性低。
  • 临床改善、临床恶化及严重不良事件数据有限,均无显著差异。

适用人群与场景

  • 确诊或疑似COVID-19患者,任何治疗场景。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,纳入随机对照试验。
  • 样本量:主要分析4项同行评议RCT共1060例;次要分析另纳入6项其他公开RCT共10722例。
  • 干预与对照:任何类型的恢复期血浆 vs 安慰剂或标准治疗。
  • 主要终点(全因死亡):4项同行评议RCT的汇总RR 0.93(95%CI 0.63-1.38),绝对风险差-1.21%(95%CI -5.29%-2.88%),证据确定性低(不精确)。
  • 全部10项RCT的汇总RR 1.02(95%CI 0.92-1.12),证据确定性中等(因纳入未发表数据)。
  • 关键次要终点:住院时长HR 1.17(95%CI 0.07-20.34),证据确定性低;机械通气使用RR 0.76(95%CI 0.20-2.87),绝对风险差-2.56%(95%CI -13.16%-8.05%),证据确定性低。
  • 临床改善、临床恶化及严重不良事件数据有限,均无显著差异。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入随机对照试验。
  • 证据确定性:全因死亡为低至中等,其他结局为低(采用GRADE评估)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 恢复期血浆与安慰剂或标准治疗相比,未显著降低全因死亡率,其他临床结局亦无显著获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Convalescent plasma is a proposed treatment for COVID-19.

OBJECTIVE: To assess clinical outcomes with convalescent plasma treatment vs placebo or standard of care in peer-reviewed and preprint publications or press releases of randomized clinical trials (RCTs).

DATA SOURCES: PubMed, the Cochrane COVID-19 trial registry, and the Living Overview of Evidence platform were searched until January 29, 2021.

STUDY SELECTION: The RCTs selected compared any type of convalescent plasma vs placebo or standard of care for patients with confirmed or suspected COVID-19 in any treatment setting.

DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data on relevant clinical outcomes, trial characteristics, and patient characteristics and used the Cochrane Risk of Bias Assessment Tool. The primary analysis included peer-reviewed publications of RCTs only, whereas the secondary analysis included all publicly available RCT data (peer-reviewed publications, preprints, and press releases). Inverse variance-weighted meta-analyses were conducted to summarize the treatment effects. The certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation.

MAIN OUTCOMES AND MEASURES: All-cause mortality, length of hospital stay, clinical improvement, clinical deterioration, mechanical ventilation use, and serious adverse events.

RESULTS: A total of 1060 patients from 4 peer-reviewed RCTs and 10 722 patients from 6 other publicly available RCTs were included. The summary risk ratio (RR) for all-cause mortality with convalescent plasma in the 4 peer-reviewed RCTs was 0.93 (95% CI, 0.63 to 1.38), the absolute risk difference was -1.21% (95% CI, -5.29% to 2.88%), and there was low certainty of the evidence due to imprecision. Across all 10 RCTs, the summary RR was 1.02 (95% CI, 0.92 to 1.12) and there was moderate certainty of the evidence due to inclusion of unpublished data. Among the peer-reviewed RCTs, the summary hazard ratio was 1.17 (95% CI, 0.07 to 20.34) for length of hospital stay, the summary RR was 0.76 (95% CI, 0.20 to 2.87) for mechanical ventilation use (the absolute risk difference for mechanical ventilation use was -2.56% [95% CI, -13.16% to 8.05%]), and there was low certainty of the evidence due to imprecision for both outcomes. Limited data on clinical improvement, clinical deterioration, and serious adverse events showed no significant differences.

CONCLUSIONS AND RELEVANCE: Treatment with convalescent plasma compared with placebo or standard of care was not significantly associated with a decrease in all-cause mortality or with any benefit for other clinical outcomes. The certainty of the evidence was low to moderate for all-cause mortality and low for other outcomes.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA. 2021. PMID: 33635310. doi:10.1001/jama.2021.2747

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。